15 enrolling by invitation. 15 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Enrolling by invitation 15 |
| Phase 1 | 4 | Enrolling by invitation 4 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer MRG003 (Becotatug Vedotin) - Biliary Tract Neoplasms | Phase 2 | Enrolling by invitation | Jiangmen Central Hospital | 30 | 2026-09-22 | 2026-10-26 |
| Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma Hypofractionated Radiation Therapy - Anal Cancer | Phase 2 | Enrolling by invitation | University of Vermont Medical Center | 24 | 2026-08-26 | 2026-09-15 |
| Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction laparoscopic and endoscopic cooperative surgery - Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Enrolling by invitation | Peking University People's Hospital | 40 | 2026-04-01 | 2026-04-30 |
| Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg - Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer | Phase 2 | Enrolling by invitation | Hoag Memorial Hospital Presbyterian | 39 | 2026-03-05 | 2026-09-23 |
| Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma Nimotuzumab, camrelizumab, Albumin paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Enrolling by invitation | Peking University | 48 | 2025-11-01 | 2025-12-31 |
| Patients With High-grade Pancreatic Neuroendocrine Tumors Lurbinectedin 4 MG Injection [Zepzelca] - Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors | Phase 2 | Enrolling by invitation | National Cancer Center, Korea | 46 | 2025-09-23 | 2025-10-01 |
| Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy - Colorectal Cancer, Gastric Cancer | Phase 2 | Enrolling by invitation | Blokhin's Russian Cancer Research Center | 128 | 2025-06-03 | 2026-04-24 |
| XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI, Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI - Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation | Phase 1 / Phase 2 | Enrolling by invitation | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-05-23 | 2026-09-25 |
| Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer Treatment :Gemcitabine plus Nab-Paclitaxel (AG regimen) in combination with Iparomlimab and Tuvorili - Gallbladder Cancer Unresectable | Phase 2 | Enrolling by invitation | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 44 | 2025-05-01 | 2025-12-30 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1 - Gallbladder Cancer and Extrahepatic Cholangiocarcinoma | Phase 2 | Enrolling by invitation | The First Affiliated Hospital of Zhengzhou University | 50 | 2024-11-08 | 2025-03-30 |
| Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT) Gemcitabine nab-PaclitaxelLenvatinibTislelizumab - Gallbladder Cancer, Cholangiocarcinoma | Phase 2 | Enrolling by invitation | Wei Gong | 44 | 2024-06-01 | 2025-05-08 |
| Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors - Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Man Hu | 100 | 2024-03-30 | 2025-03-30 |
| Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma paclitaxel, carboplatin, tislelizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Qiu Guoqin | 30 | 2022-06-01 | 2024-03-12 |
| A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w, ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg, ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg - Hepatocellular Carcinoma | Phase 2 | Enrolling by invitation | Abbisko Therapeutics Co, Ltd | 118 | 2021-12-30 | 2026-02-25 |
Gallbladder Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Adenoma, Islet Cell (1) · Anus Neoplasms (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Gastrointestinal Stromal Tumors (1) · Glioblastoma (1) · Mesothelioma, Malignant (1) · Neuroendocrine Tumors (1)
Digestive System Diseases (15) · Neoplasms (15) · Neoplasms by Site (14) · Neoplasms by Histologic Type (9) · Gastrointestinal Diseases (8) · Gastrointestinal Neoplasms (8) · Neoplasms, Glandular and Epithelial (8) · Carcinoma (6) · Biliary Tract Diseases (4) · Esophageal Diseases (4) · Head and Neck Neoplasms (4) · Adenocarcinoma (3) · Biliary Tract Neoplasms (3) · Carcinoma, Squamous Cell (3)
130-nm albumin-bound paclitaxel (2) · camrelizumab (2) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Drug Therapy (1) · Folfox protocol (1) · Injections (1) · Laparoscopy (1) · Nivolumab (1) · PM 01183 (1) · Paclitaxel (1) · Radiotherapy (1) · S 1 (combination) (1) · anlotinib (1)
Abbisko Therapeutics Co, Ltd (1) · Blokhin's Russian Cancer Research Center (1) · Hoag Memorial Hospital Presbyterian (1) · Jiangmen Central Hospital (1) · Man Hu (1) · National Cancer Center, Korea (1) · Peking University (1) · Peking University People's Hospital (1) · Qiu Guoqin (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Stella Pharma Corporation (1) · The First Affiliated Hospital of Zhengzhou University (1) · University of Vermont Medical Center (1) · Wei Gong (1) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1)
China (10) · United States (2) · Japan (1) · Russia (1) · South Korea (1)
Carlos Becerra, MD (1) · Christopher L Anker, MD (1) · Man Hu, Dr. (1) · Wei Gong (1) · Zhihao MM Lu, PHD (1)